6XA9

SARS CoV-2 PLpro in complex with ISG15 C-terminal domain propargylamide

6XA9 の概要

• エントリーDOI: 10.2210/pdb6xa9/pdb
• 分子名称: Non-structural protein 3, ISG15 CTD-propargylamide, GLYCEROL, ... (5 entities in total)
• 機能のキーワード: sars cov-2, papain-like protease, isg15ctd activity based probe, covid19, hydrolase-substrate complex, hydrolase/substrate
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 135954.60

構造登録者

Klemm, T.,Calleja, D.J.,Richardson, L.W.,Lechtenberg, B.C.,Komander, D. (登録日: 2020-06-04, 公開日: 2020-06-17, 最終更新日: 2023-10-18)

• 主引用文献: Klemm, T.,Ebert, G.,Calleja, D.J.,Allison, C.C.,Richardson, L.W.,Bernardini, J.P.,Lu, B.G.,Kuchel, N.W.,Grohmann, C.,Shibata, Y.,Gan, Z.Y.,Cooney, J.P.,Doerflinger, M.,Au, A.E.,Blackmore, T.R.,van der Heden van Noort, G.J.,Geurink, P.P.,Ovaa, H.,Newman, J.,Riboldi-Tunnicliffe, A.,Czabotar, P.E.,Mitchell, J.P.,Feltham, R.,Lechtenberg, B.C.,Lowes, K.N.,Dewson, G.,Pellegrini, M.,Lessene, G.,Komander, D.; Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.; Embo J., 39:e106275-e106275, 2020; PubMed: 32845033; DOI: 10.15252/embj.2020106275

実験手法

X-RAY DIFFRACTION (2.9 Å)